26
|
Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid H, van der Kwast T, Wiegel T, Zattoni F. Guía de la EAU sobre el cáncer de próstata: Parte I: cribado, diagnóstico y tratamiento del cáncer clínicamente localizado. Actas Urol Esp 2011. [DOI: 10.4321/s0210-48062011000900001] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
27
|
Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid H, van der Kwast T, Wiegel T, Zattoni F. EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease. ACTA ACUST UNITED AC 2011. [DOI: 10.1016/j.acuroe.2011.12.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
28
|
Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F. [EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease]. Actas Urol Esp 2011; 35:501-14. [PMID: 21757259 DOI: 10.1016/j.acuro.2011.04.004] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2011] [Accepted: 03/11/2011] [Indexed: 12/21/2022]
Abstract
OBJECTIVE Our aim was to present a summary of the 2010 version of the European Association of Urology (EAU) guidelines on the screening, diagnosis, and treatment of clinically localised cancer of the prostate (PCa). METHODS The working panel performed a literature review of the new data emerging from 2007 to 2010. The guidelines were updated, and level of evidence and grade of recommendation were added to the text based on a systematic review of the literature, which included a search of online databases and bibliographic reviews. RESULTS A full version is available at the EAU office or Web site (www.uroweb.org). Current evidence is insufficient to warrant widespread population-based screening by prostate-specific antigen (PSA) for PCa. A systematic prostate biopsy under ultrasound guidance and local anaesthesia is the preferred diagnostic method. Active surveillance represents a viable option in men with low-risk PCa and a long life expectancy. PSA doubling time in < 3 yr or a biopsy progression indicates the need for active intervention. In men with locally advanced PCa in whom local therapy is not mandatory, watchful waiting (WW) is a treatment alternative to androgen-deprivation therapy (ADT) with equivalent oncologic efficacy. Active treatment is mostly recommended for patients with localised disease and a long life expectancy with radical prostatectomy (RP) shown to be superior to WW in a prospective randomised trial. Nerve-sparing RP represents the approach of choice in organ-confined disease; neoadjuvant androgen deprivation demonstrates no improvement of outcome variables. Radiation therapy should be performed with at least 74Gy and 78Gy in low-risk and intermediate/high-risk PCa, respectively. For locally advanced disease, adjuvant ADT for 3 yr results in superior disease-specific and overall survival rates and represents the treatment of choice. Follow-up after local therapy is largely based on PSA, and a disease-specific history with imaging is indicated only when symptoms occur. CONCLUSIONS The knowledge in the field of PCa is rapidly changing. These EAU guidelines on PCa summarise the most recent findings and put them into clinical practice.
Collapse
|
29
|
Bolla M, Giraud JY, Descotes JL, Long JA, Hungr N, Baumann M, Troccaz J. Curiethérapie du cancer de prostate assistée par échographie tridimensionnelle et robot. Cancer Radiother 2011. [DOI: 10.1016/j.canrad.2011.07.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
30
|
Bosset J, Puyraveau M, Mineur L, Calais G, Bardet E, Maingon P, Bolla M, Collette L, Mercier M. 6018 POSTER DISCUSSION EORTC 22921 Rectal Cancer Trial: Quality of Life (QoL) and Functional Outcome 5 Years After Treatment. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71663-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
31
|
Perrotta A, Serrao M, Coppola G, Ambrosini A, Bolla M, Sandrini G, Pierelli F. P23.16 Dysfunctional supraspinal control of pain in cluster headache. Clin Neurophysiol 2011. [DOI: 10.1016/s1388-2457(11)60602-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
32
|
Bolla M. 335 speaker PROSTATE CANCER: ADJUVANT ANDROGEN DEPRIVATION THERAPY IN THE ERA OF NEW TECHNOLOGIES AND DOSE ESCALATION. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)70457-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
33
|
Baumann M, Bolla M, Daanen V, Descotes JL, Giraud JY, Hungr N, Leroy A, Long JA, Martin S, Troccaz J. Prosper: Image and robot-guided prostate brachytherapy. Ing Rech Biomed 2011. [DOI: 10.1016/j.irbm.2011.01.019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
Van Poppel H, Bolla M, Tombal B, Vekemans K, Da Pozzo L, De Reijke T, Verbaeys A, Bosset J, Van Velthoven R, Colombel M, Van De Beek C, Verhagen P, Van Den Bergh A, Sternberg C, Gasser T, Van Tienhoven G, Scalliet P, Haustermans K, Collette L. 227 ADJUVANT RADIOTHERAPY AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH PATHOLOGICALLY HIGH RISK PROSTATE CANCER: 10-YEAR FOLLOW-UP RESULTS. ACTA ACUST UNITED AC 2011. [DOI: 10.1016/s1569-9056(11)60227-3] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
35
|
Bolla M, Van Poppel H, Tombal B, Vekemans K, Da Pozzo L, De Reijke T, Verbaeys A, Bosset J, Van Velthoven R, Collette L. 10-year Results of Adjuvant Radiotherapy after Radical Prostatectomy in pT3N0 Prostate Cancer (EORTC 22911). Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.107] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
36
|
Hansen JM, Bolla M, Magis D, de Pasqua V, Ashina M, Thomsen LL, Olesen J, Schoenen J. Habituation of evoked responses is greater in patients with familial hemiplegic migraine than in controls: a contrast with the common forms of migraine. Eur J Neurol 2010; 18:478-85. [DOI: 10.1111/j.1468-1331.2010.03190.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
37
|
Fuse S, Tsukamoto H, Yuan Y, Wang TSA, Zhang Y, Bolla M, Walker S, Sliz P, Kahne D. Functional and structural analysis of a key region of the cell wall inhibitor moenomycin. ACS Chem Biol 2010; 5:701-11. [PMID: 20496948 DOI: 10.1021/cb100048q] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Moenomycin A (MmA) belongs to a family of natural products that inhibit peptidoglycan biosynthesis by binding to the peptidoglycan glycosyltransferases, the enzymes that make the glycan chains of peptidoglycan. MmA is remarkably potent, but its clinical utility has been hampered by poor physicochemical properties. Moenomycin contains three structurally distinct regions: a pentasaccharide, a phosphoglycerate, and a C25 isoprenyl (moenocinyl) lipid tail that gives the molecule its name. The phosphoglycerate moiety links the pentasaccharide to the moenocinyl chain. This moiety contains two negatively charged groups, a phosphoryl group and a carboxylate. Both the phosphoryl group and the carboxylate have previously been implicated in target binding but the role of the carboxylate has not been explored in detail. Here we report the synthesis of six MmA analogues designed to probe the importance of the phosphoglycerate. These analogues were evaluated for antibacterial and enzyme inhibitory activity; the specific contacts between the phosphoglycerate and the protein target were assessed by X-ray crystallography in conjunction with molecular modeling. Both the phosphoryl group and the carboxylate of the phosphoglycerate chain play roles in target binding. The negative charge of the carboxylate, and not its specific structure, appears to be the critical feature in binding since replacing it with a negatively charged acylsulfonamide group produces a more active compound than replacing it with the isosteric amide. Analysis of the ligand-protein contacts suggests that the carboxylate makes a critical contact with an invariant lysine in the active site. The reported work provides information and validated computational methods critical for the design of analogues based on moenomycin scaffolds.
Collapse
|
38
|
Drouin S, Rouprêt M, Bossi A, Bolla M. Hormonothérapie combinée à la radiothérapie externe dans le cancer de prostate localement avancé : les effets secondaires contrecarrent-ils les bénéfices ? Prog Urol 2010; 20 Suppl 3:S186-91. [DOI: 10.1016/s1166-7087(10)70037-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
39
|
Matzinger O, Duclos F, Bergh AVD, Carrie C, Villà S, Kitsios P, Poortmans P, Sundar S, van der Steen-Banasik E, Gulyban A, Collette L, Bolla M. Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991. Eur J Cancer 2009; 45:2825-34. [DOI: 10.1016/j.ejca.2009.07.009] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2009] [Revised: 07/14/2009] [Accepted: 07/17/2009] [Indexed: 11/24/2022]
|
40
|
Chauvet B, Bolla M, Alies-Patin A, Bara C, Bourguignon M, Chantôme G, Eschwège F, Estivalet S, Fau P, Fournie E, Lipinski F, Mazeron JJ, Mornex F, Pointreau Y, Weissmann H. Observatoire national de la radiothérapie : rapport de l’enquête conduite en 2008 sur l’année 2007. Cancer Radiother 2009; 13:466-70. [DOI: 10.1016/j.canrad.2009.07.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2009] [Accepted: 07/07/2009] [Indexed: 11/30/2022]
|
41
|
Matzinger O, Duclos F, van den Bergh A, Carrie C, Kitsios P, Villà S, Poortmans P, Sundar S, Collette L, Bolla M. 2001 Acute toxicity of curative radiotherapy for intermediate risk localized prostate cancer in the EORTC trial 22991. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)70517-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
42
|
Rossi P, Schoenen J, Bolla M, Tassorelli C, Sandrini G, Nappi G. Implementation and evaluation of existing guidelines on the use of neurophysiological tests in non-acute migraine patients: a questionnaire survey of neurologists and primary care physicians. Eur J Neurol 2009; 16:937-42. [PMID: 19456856 DOI: 10.1111/j.1468-1331.2009.02630.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND AND PURPOSE The main aims of this study were to evaluate: the diffusion, use and perception of the usefulness of the 2004 EFNS guidelines on neurophysiological testing in non-acute headache patients; the frequency with which the different neurophysiological tests were recommended in non-acute migraine patients by physicians aware or unaware of the guidelines; and the appropriateness of the reasons given for recommending neurophysiological tests. METHODS One hundred and fifty physicians selected amongst the members of the Italian societies of general practitioner (GPs), neurologists and headache specialists were contacted via e-mail and invited to fill in a questionnaire specially created for the study. RESULTS Ninety-two percent of the headache specialists, 8.6% of the neurologists and 0% of the GPs were already aware of the EFNS guidelines. A significantly higher proportion of headache specialists had not recommended any neurophysiological tests to the migraine patients they had seen in the previous 3 months, whereas these tests had frequently been prescribed by the GPs and neurologists. Overall, 80%, 42% and 42.6% of the reasons given by headache specialists, neurologists and GPs, respectively, for recommending neurophysiological testing in their migraine patients were appropriate (P < 0.01). CONCLUSIONS The diffusion of the EFNS guidelines on neurophysiological tests and neuroimaging procedures was found to be very limited amongst neurologists and GPs. The physicians aware of the EFNS guidelines recommended neurophysiological tests to migraine patients less frequently and more appropriately than physicians who were not aware of them. The most frequent misconceptions regarding neurophysiological tests concerned their perceived capacity to discriminate between migraine and secondary headaches or between migraine and other primary headaches.
Collapse
|
43
|
Di Lorenzo C, Pierelli F, Coppola G, Grieco GS, Rengo C, Ciccolella M, Magis D, Bolla M, Casali C, Santorelli FM, Schoenen J. Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology 2009; 72:1588-94. [DOI: 10.1212/wnl.0b013e3181a41269] [Citation(s) in RCA: 67] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
44
|
Bolla M, Collette L, Van Tienhoven G, Warde P, Dubois J, Mirimanoff R, Storme G, Bernier J, Kuten A, Piérart M. Ten Year Results of Long Term Adjuvant Androgen Deprivation with Goserelin in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy: A Phase III EORTC Study. Int J Radiat Oncol Biol Phys 2008. [DOI: 10.1016/j.ijrobp.2008.06.834] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
45
|
Poortmans PM, Collette L, Bartelink H, Struikmans H, Van den Bogaert WF, Fourquet A, Jager JJ, Hoogenraad W, Müller RP, Dubois JB, Bolla M, Van Der Hulst M, Wárlám-Rodenhuis CC, Pierart M, Horiot JC. The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial. Cancer Radiother 2008; 12:565-70. [PMID: 18760649 DOI: 10.1016/j.canrad.2008.07.014] [Citation(s) in RCA: 73] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2008] [Accepted: 07/09/2008] [Indexed: 11/17/2022]
Abstract
PURPOSE To investigate the impact of the boost dose to the primary tumour bed in the framework of breast conserving therapy on local control, cosmetic results, fibrosis and overall survival for patients with early stage breast cancer. PATIENTS AND METHODS Five thousand five hundred and sixty-nine patients after lumpectomy followed by whole breast irradiation of 50 Gy were randomised. After a microscopically complete lumpectomy (5318 patients), the boost doses were either 0 or 16 Gy, while after a microscopically incomplete (251 patients) lumpectomy randomisation was between 10 and 26 Gy. The results at a median follow-up of 10 years are presented. RESULTS At 10 years, the cumulative incidence of local recurrence was 10.2% versus 6.2% for the 0 Gy and the 16 Gy boost groups (p < 0.0001) and 17.5% versus 10.8% for the 10 and 26 Gy boost groups, respectively (p > 0.1). There was no statistically significant interaction per age group but recurrences tended to occur earlier in younger patients. As younger patients had a higher cumulative risk of local relapse by year 10, the magnitude of the absolute 10-year risk reduction achieved with the boost decreased with increasing age. Development of fibrosis was significantly dependent on the boost dose with a 10-year rate for severe fibrosis of 1.6% after 0 Gy, 3.3% after 10 Gy, 4.4% after 16 Gy and 14.4% after 26 Gy, respectively. CONCLUSION An increase of the dose with 16 Gy improved local control for patients after a complete lumpectomy only. The development of fibrosis was clearly dose dependent. With 10 years median follow-up, no impact of survival was observed.
Collapse
|
46
|
Kaddai V, Gonzalez T, Bolla M, Le Marchand-Brustel Y, Cormont M. The nitric oxide-donating derivative of acetylsalicylic acid, NCX 4016, stimulates glucose transport and glucose transporters translocation in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2008; 295:E162-9. [PMID: 18492771 DOI: 10.1152/ajpendo.00622.2007] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
NCX 4016 is a nitric oxide (NO)-donating derivative of acetylsalicylic acid. NO and salicylate, in vivo metabolites of NCX 4016, were shown to be potential actors in controlling glucose homeostasis. In this study, we evaluated the action of NCX 4016 on the capacity of 3T3-L1 adipocytes to transport glucose in basal and insulin-stimulated conditions. NCX 4016 induced a twofold increase in glucose uptake in parallel with the translocation of the glucose transporters GLUT1 and GLUT4 to the plasma membrane, leaving unaffected their total expression levels. Importantly, NCX 4016 further increased glucose transport induced by a physiological concentration of insulin. The stimulatory effect of NCX 4016 on glucose uptake appears to be mediated by its NO moiety. Indeed, it is inhibited by a NO scavenger and treatment with acetylsalicylic or salicylic acid had no effect. Although NO is involved in the action of NCX 4016, it did not mainly depend on the soluble cGMP cyclase/protein kinase G pathway. Furthermore, NCX 4016-stimulated glucose transport did not involve the insulin-signaling cascade required to stimulate glucose transport. NCX 4016 induces a small activation of the mitogen-activated protein kinases p38 and c-Jun NH(2)-terminal kinase and no activation of other stress-activated signaling molecules, including extracellular signal-regulated kinase, inhibitory factor kappaB, or AMP-activated kinases. Interestingly, NCX 4016 modified the content of S-nitrosylated proteins in adipocytes. Taken together, our results indicate that NCX 4016 induced glucose transport in adipocytes through a novel mechanism possibly involving S-nitrosylation. NCX 4016 thus possesses interesting characteristics to be considered as a candidate molecule for the treatment of patients suffering from metabolic syndrome and type 2 diabetes.
Collapse
|
47
|
Righini CA, Faure C, Lantuejoul S, Chahine K, Soriano E, Brambilla E, Bolla M, Reyt E. Course and prognosis of basaloid squamous cell carcinoma (BSCC) of the head and neck: A case-control study of 62 patients. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.17002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
48
|
Gerard JP, Bolla M. [Safety and transparency. At the heart of the culture of radiation oncologists]. Cancer Radiother 2008; 12:141. [PMID: 18672496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
|
49
|
|
50
|
Bolla M, De Reijke T, Van Tienhoven G, Van Den Bergh A, Oddens J, Poortmans P, Gez E, Kil P, Musat E, Collette L. SIX-MONTH CONCOMITANT AND ADJUVANT HORMONAL TREATMENT WITH EXTERNAL BEAM IRRADIATION IS INFERIOR TO 3-YEARS HORMONAL TREATMENT FOR LOCALLY ADVANCED PROSTATE CANCER: RESULTS OF THE EORTC RANDOMISED PHASE III TRIAL 22961. ACTA ACUST UNITED AC 2008. [DOI: 10.1016/s1569-9056(08)60185-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|